Raphael M.
- Country
- Germany
- Department
- Medizinische Klinik m. S. Hepatologie und Gastroenterologie
Research Overview
- Safety and Efficacy of PF-08634404 as Monotherapy and in Combination with Ipilimumab in Adults with Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
- Evaluation of Durvalumab and Bevacizumab as Adjuvant Therapy in High-Risk Hepatocellular Carcinoma Post-Curative Resection or Ablation
- Evaluation of Fecal Microbiota Transfer to Overcome Atezolizumab and Bevacizumab Resistance in Advanced Hepatocellular Carcinoma: A Phase II Randomized Controlled Trial
Data & Insights
Has run more than one trial at 44 of 95 partner sites.
Specializations
Liver Cancer Treatment
This investigator specializes in advanced therapeutic approaches for hepatocellular carcinoma (HCC), with particular focus on immunotherapy treatments and innovative drug combinations.
- Advanced stage HCC management
- Immunotherapy combinations
- Post-resection treatment strategies
The research encompasses various treatment modalities for both early-stage and advanced liver cancer.
Immunotherapy Innovation
The investigator explores novel immunotherapeutic approaches including the use of checkpoint inhibitors such as durvalumab, tremelimumab, and nivolumab in liver cancer treatment.
- Combination immunotherapy protocols
- Treatment resistance mechanisms
- Novel therapeutic combinations
Research focuses on optimizing immunotherapy responses in hepatocellular carcinoma patients.
Therapeutic Innovation
Investigation of cutting-edge approaches including microbiota-based treatments and targeted therapies for liver cancer, particularly in cases resistant to conventional treatments.
- Microbiota transfer therapy
- Targeted therapeutic approaches
- Treatment resistance solutions
The work extends to developing strategies for overcoming treatment resistance in advanced liver cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.